Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jun 07, 2022 5:24pm
175 Views
Post# 34738447

RE:RE:FWIW

RE:RE:FWIWIndeed the darn Convert will become a current liability ...near th end of June...However the second Quarter ended May 31 willstill show a positive working capital...So it sort of means that they need to be able to refinance the Convert or renegotiate the terms before the end of August (3rd quarter) Otherwise the Balance Sheet will show a serious working capital deficiency

I have very little trust in the CFO s ability ....but a lot of trust in the CEO......



jeffm34 wrote: It's really mind boggling how this company thinks they can keep spending like drunken sailors with so many new hires.  Is there anyone there that has any business sense at all. In just over 3 weeks the company will have negative working capital. Any hope of positive trial data coming out before the next financing is out the window. The only way they get more money is at the expense of current share holders. 


<< Previous
Bullboard Posts
Next >>